Australia markets close in 3 hours 49 minutes
  • ALL ORDS

    7,356.40
    -35.30 (-0.48%)
     
  • ASX 200

    7,123.40
    -31.80 (-0.44%)
     
  • AUD/USD

    0.7086
    -0.0003 (-0.05%)
     
  • OIL

    110.42
    +0.09 (+0.08%)
     
  • GOLD

    1,847.50
    +1.20 (+0.06%)
     
  • BTC-AUD

    41,969.60
    -396.90 (-0.94%)
     
  • CMC Crypto 200

    660.04
    -10.97 (-1.63%)
     
  • AUD/EUR

    0.6620
    -0.0009 (-0.14%)
     
  • AUD/NZD

    1.0941
    0.0000 (0.00%)
     
  • NZX 50

    11,214.60
    +41.23 (+0.37%)
     
  • NASDAQ

    11,943.93
    +174.09 (+1.48%)
     
  • FTSE

    7,522.75
    +38.40 (+0.51%)
     
  • Dow Jones

    32,120.28
    +191.66 (+0.60%)
     
  • DAX

    14,007.93
    +88.18 (+0.63%)
     
  • Hang Seng

    19,934.13
    -237.14 (-1.18%)
     
  • NIKKEI 225

    26,641.78
    -36.02 (-0.14%)
     

Geron to Present at the H.C. Wainwright BioConnect Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

FOSTER CITY, Calif., January 04, 2022--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference.

The pre-recorded company presentation will be available beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022 using the following link: https://journey.ct.events/view/0a8abdcd-614c-42a5-86d4-1b5902e19d32 and will also be available on the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104006038/en/

Contacts

Olivia Bloom
Chief Financial Officer
investor@geron.com
media@geron.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting